Feasibility of Percutaneous Radiofrequency Ablation for Pulmonary Malignancies in the Hands of the Surgeon

Hublet, A; Wijtenburg, E.; Lismonde, M.; Thomas, T.J.; Majois, F; Lovinfosse, S de; Delaunoit, Thierry; Mitine, C.; Vermonden, J; Nicaise, G; Ruyssevelt, P. Van

doi:10.1080/00015458.2010.11680615

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these studies, six included patients with NSCLCs and metastatic lung disease originating from other primary tumors [13,44,45,46,47,48,49,50,51], three included only patients with colorectal metastases [52,53,54], two included patients with renal metastases [55,56], and four studies included only patients with inoperable NSCLC [57,58,59,60]. Most of these studies included patients with stage I carcinoma, and numbers of patients in each of the above series ranged from 18 to 153.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Potential MicroRNA Mechanism for Computed Tomography-Guided Percutaneous Radiofrequency Ablation of Primary Lung Cancer and Lung Metastasis from Liver Cancer

Zhang²,

Liu³

et al. 2014

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate comparatively the effectiveness of computed tomography-guided percutaneous radiofrequency ablation (CT-PRFA) for primary non-small cell lung cancer (NSCLC) and lung metastases from hepatocellular carcinoma (HCC) and to explore the potential miRNA mechanisms for the efficacy of CT-PRFA. Methods: 14 patients pathologically diagnosed with NSCLC and 12 patients with lung metastases from HCC were enrolled in the study and underwent CT-PRFA. Clinical outcomes were compiled on the basis of review of medical records, imaging follow-up reports, and any biopsy-proved residual or recurrent disease. Real-time RT-PCR was used to quantify the selected miRNAs known to be play key roles in lung cancer. Results: A total of 21 tumors were treated with umbrella-tip electrodes and spiral-tip electrodes were used for the remaining 8 tumors. The median follow-up was 13.5 months (range, 3-30 months) and no patient was lost to follow-up. The rate of technique efficacy for primary tumors was ∼93% (13 of 14). Treatment was successful in 11 out of 12 (91.7%) lung metastases patients. Overall survival rate was 80.8% at 2 years, and cancer-specific survival rate was 100% at 2 years. The tumor-free survival was 69.2% at 1 year and 26.9% at 2 years. Before PRFA, tumor suppressor let-7a and miR-34a were downregulated whereas oncomiR miR-21 was upregulated in primary tumors, and let-7a and miR-126 levels were downregulated whereas oncomiRs miR-21, miR-155 and miR-17-5p/miR-20b levels were upregulated in secondary tumors. This abnormal expression was normalized by CT-PRFA. Most notably, CT-PRFA failed to normalize the deregulated miRNAs in the non-survivors. Conclusions: CT-PRFA is a effective treatment for primary NSCLCs and secondary lung tumors from HCC and the efficacy may be related to its ability to normalize deregulated expression of miRNAs: upregulating tumor suppressor miRNAs and downregulating oncomiRs.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Potential MicroRNA Mechanism for Computed Tomography-Guided Percutaneous Radiofrequency Ablation of Primary Lung Cancer and Lung Metastasis from Liver Cancer

Zhang²,

Liu³

et al. 2014

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

Evaluation of carcinoembryonic antigen (CEA) density as a prognostic factor for percutaneous ablation of pulmonary colorectal metastases

et al. 2016

View full text Add to dashboard Cite

show abstract

Radiofrequency ablation of small renal masses as an alternative to nephron-sparing surgery: preliminary results.

Jasiński¹,

Siekiera²,

Chłosta³

et al. 2011

Videosurgery and Other Miniinvasive Techniques

View full text Add to dashboard Cite

IntroductionRadical endoscopic minimal-invasive treatment methods, such as thermal ablation, are sought as an alternative to standard radical surgical treatment of kidney neoplasms. We analysed patients who could be qualified for radical treatment due to T1a renal tumour.Material and methodsTwenty-three patients out of 129 who underwent radiofrequency thermal ablation of kidney tumours in the years 2003-2010 were analysed. The inclusion criteria were age below 70 years, lack of major comorbidities (ASA score 1, 2), and competent contralateral kidney. In all cases tumour size was below 4 cm. All patients were followed up with computed tomography (CT) and ultrasonography (USG) every 6 months for 3 years.ResultsIn 20 patients kidney tumour was biopsied before radiofrequency ablation (RFA) and 10 of these biopsies were positive and revealed cancer. Six patients required additional treatment due to recurrence visible in CT – 3 with a positive biopsy result, 1 with negative and 2 without biopsy. Three of them were treated with a second session of RFA, 1 with radical nephrectomy and 2 with partial nephrectomy. No disease dissemination was observed and all patients who received additional treatment remain disease free.ConclusionsThe RFA can be safely used in selected patients with T1a tumour as an alternative to partial nephrectomy. Careful follow-up is required after thermal ablation and allows early detection and successful treatment of recurrences.

show abstract

Feasibility of Percutaneous Radiofrequency Ablation for Pulmonary Malignancies in the Hands of the Surgeon

Cited by 3 publications

References 0 publications

Efficacy and Potential MicroRNA Mechanism for Computed Tomography-Guided Percutaneous Radiofrequency Ablation of Primary Lung Cancer and Lung Metastasis from Liver Cancer

Efficacy and Potential MicroRNA Mechanism for Computed Tomography-Guided Percutaneous Radiofrequency Ablation of Primary Lung Cancer and Lung Metastasis from Liver Cancer

Evaluation of carcinoembryonic antigen (CEA) density as a prognostic factor for percutaneous ablation of pulmonary colorectal metastases

Radiofrequency ablation of small renal masses as an alternative to nephron-sparing surgery: preliminary results.

Contact Info

Product

Resources

About